Trial PaperDepressive DisordersAdolescentsKetamine

A Novel, Brief, Fully Automated Intervention to Extend the Antidepressant Effect of a Single Ketamine Infusion: A Randomized Clinical Trial

This double-blind, placebo-controlled study (n=154) of ketamine (35mg/70kg) (or placebo) with (and without) positive self-regard training (automated self-association training) finds that the combination can extend the positive antidepressant (MADRS) effects of ketamine, whilst the effects of ketamine alone was not distinguishable from placebo 30 days later.

Authors

  • Sanjay Mathew

Published

American Journal of Psychiatry
individual Study

Abstract

Objective

Intravenous ketamine, which displays rapid antidepressant properties, is posited to reverse depression by rapidly enhancing neuroplasticity. The authors tested whether an automated, computer-based approach could efficiently leverage enhanced neuroplasticity to extend the durability of rapid clinical response.

Methods

A total of 154 adults (ages 18-60) with treatment-resistant unipolar depression were randomized in a double-blind, parallel-arm design to receive an active/active treatment combination (ketamine plus active “automated self-association training” [ASAT]; N=53) or one of two control arms that lacked either the active drug component (saline plus active ASAT; N=51) or the active behavioral component (ketamine plus sham ASAT; N=50). One day after a single infusion of intravenous ketamine (0.5 mg/kg over 40 minutes) or inert placebo (saline), active ASAT-targeting self-worth through automated “evaluative conditioning” training delivered by computer-or sham ASAT (consisting of identical computer tasks that included no positive or self-referential stimuli) was given, delivered twice daily over 4 consecutive days (eight sessions, ≤20 minutes per session). The prespecified primary outcome measure throughout the main (30-day) study period was score on the Montgomery-Åsberg Depression Rating Scale (MADRS).

Results

Ketamine rapidly and significantly reduced depression scores at 24 hours postinfusion (group-by-time interaction: standardized beta [β]=−1.30, 95% CI=−1.89, −0.70; t=−4.29, df=150). In intent-to-treat linear mixed models, depression scores in the ketamine+ASAT group remained significantly and stably low over the 30-day study period relative to those of the saline+ASAT group (β=−0.61, 95% CI=−0.95, −0.28; t=−3.62, df=148). By contrast, depression scores following ketamine+sham treatment followed a significant, increasing linear trajectory from 24 hours to 30 days, approaching the levels observed in the saline+ASAT group (group-by-time interaction relative to the saline+ASAT group: β=0.015, 95% CI=0.003, 0.03; t=2.35, df=568).

Conclusions

After priming the brain with ketamine, training positive self-associations could provide an efficient, low-cost, portable, noninvasive, and highly dissemination-ready strategy for leveraging and extending ketamine’s rapid antidepressant effects.

Available with Blossom Pro

Research Summary of 'A Novel, Brief, Fully Automated Intervention to Extend the Antidepressant Effect of a Single Ketamine Infusion: A Randomized Clinical Trial'

Introduction

Depression remains highly prevalent and costly, with low remission rates and high relapse despite existing treatments; only a minority of patients receive minimally adequate care. Two recent developments have generated clinical interest: rapid-acting pharmacological agents such as intravenous ketamine, which can reduce symptoms within 2–24 hours, and automated, computer-based interventions designed to alter affective processing to increase access, lower cost, and reduce burden. However, ketamine's antidepressant effects after a single infusion typically dissipate within days to weeks, and repeated infusions raise safety and feasibility concerns. The researchers designed a study to test a synergistic biobehavioural strategy: use a single ketamine infusion to transiently increase neuroplasticity and thereby create a ‘‘window of opportunity’’ during which brief, fully automated training could consolidate adaptive cognitive-affective learning and extend ketamine's antidepressant benefit. Specifically, they developed an automated self-association training (ASAT) intervention grounded in evaluative conditioning to promote positive implicit self-worth, and compared the combined ketamine+ASAT approach against two control conditions that removed either the pharmacological or behavioural component, enabling a direct test of whether ketamine and ASAT act complementarily to produce rapid and durable symptom improvement.

Expert Research Summaries

Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.

Full Text PDF

Full Paper PDF

Create a free account to open full-text PDFs.

Study Details

  • Study Type
    individual
  • Journal
  • Compound
  • Topics
  • Author
  • APA Citation

    Price, R. B., Spotts, C., Panny, B., Griffo, A., Degutis, M., Cruz, N., Bell, E., Do-Nguyen, K., Wallace, M. L., Mathew, S. J., & Howland, R. H. (2022). A Novel, Brief, Fully Automated Intervention to Extend the Antidepressant Effect of a Single Ketamine Infusion: A Randomized Clinical Trial. American Journal of Psychiatry, 179(12), 959-968. https://doi.org/10.1176/appi.ajp.20220216

References (7)

Papers cited by this study that are also in Blossom

Ketamine and Other NMDA Antagonists: Early Clinical Trials and Possible Mechanisms in Depression

Newport, D. J., Carpenter, L. L., Mcdonald, W. M. et al. · American Journal of Psychiatry (2015)

Modulation of the antidepressant effects of ketamine by the mTORC1 inhibitor rapamycin

Abdallah, C. G., Averill, L. A., Gueorguieva, R. et al. · Neuropsychopharmacology (2020)

106 cited
Antidepressant Efficacy of Ketamine in Treatment-Resistant Major Depression: A Two-Site Randomized Controlled Trial

Murrough, J. W., Iosifescu, D. V., Chang, L. C. et al. · American Journal of Psychiatry (2013)

Cited By (5)

Papers in Blossom that reference this study

Trial of Ketamine Masked by Surgical Anesthesia in Depressed Patients

Lii, T. R., Smith, A. E., Flohr, J. R. et al. · Nature Mental Health (2023)

68 cited
History repeating: guidelines to address common problems in psychedelic science

Van Elk, M., Fried, E. I. · Therapeutic Advances in Psychopharmacology (2023)

94 cited
Must Psilocybin Always “Assist Psychotherapy”?

Goodwin, G. M., Malievskaia, E., Fonzo, G. A. et al. · American Journal of Psychiatry (2023)

6 cited

Your Personal Research Library

Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.

A Novel, Brief, Fully Automated Intervention to... — Research Summary & Context | Blossom